During the past decade, Emory Heart and Vascular Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Emory Heart and Vascular Center" are "Amyloid Cardiomyopathy" (1 trials), "Amyloidosis" (1 trials), "Cardiomyopathies" (1 trials), "Heart Diseases" (1 trials) and "Transthyretin Amyloidosis" (1 trials). Many other conditions were trialed in "Emory Heart and Vascular Center" in a lesser frequency.

Most popular intervention types in "Emory Heart and Vascular Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Acoramidis (AG10)" (1 trials), "Placebo Oral Tablet" (1 trials) and "acoramidis" (1 trials). Other intervention names were less common.

The vast majority of trials in "Emory Heart and Vascular Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Emory Heart and Vascular Center". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were undefined completed trials in Emory Heart and Vascular Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Emory Heart and Vascular Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".